According to the latest announcement released by AIM Vaccine on March the 8th, the company plans to issue non-publicly traded RMB ordinary shares (i.e. domestic shares and/or non-publicly traded foreign shares) based on specific authorization. The funds raised will be used for constructing new production facilities for bivalent EV71-CA16 HFMD vaccines, developing COVID-19 variant mRNA vaccines (including but not limited to monovalent and multivalent vaccines targeting Omicron BA.5) and multivalent pneumococcal conjugate vaccines in the pipeline, supplementing operational capital, and for general corporate purposes.

According to market analysts, the domestic shares issued by AIM Vaccine in this targeted offering can only exit through A-shares in the future, indicating a clear sign of the company's intentions for an A-share listing.

In the past February, Hang Seng Indexes announced that AIM Vaccine would be added to the Hang Seng Composite Index since March 13, 2023.

Then in March, according to the latest announcements released by the Shanghai and Shenzhen Stock Exchanges, AIM Vaccine (06660.HK) was included in the first batch of newly added Hong Kong Stock Connect targets for both Shanghai and Shenzhen markets, which will also take effect since March 13, 2023.

AIM Vaccine’s entrance into the Hang Seng Composite Index and selection as a Hong Kong Stock Connect target for both Shanghai and Shenzhen markets shortly after undoubtedly will bring more market attention to the company, expand its investor base and promote long-term sustainable development.

Various signs indicate that AIM Vaccine is continuously opening up to investors in the A-share market with a more open attitude. So what investment value does AIM Vaccine have for investors, especially mainland investors?

As a leading domestic vaccine company, AIM Vaccine has 8 commercialized vaccine products targeting 6 diseases in China’s market, including rabies, hepatitis B, hepatitis A, mumps, HFRS and meningococcal infection). AIM Vaccine has established its absolute dominance in two products, hepatitis B vaccine and rabies vaccine.

According to the batch issuance volume in 2021, AIM Vaccine is the largest supplier of hepatitis B vaccines both in China and globally and the second-largest manufacturer of human rabies vaccines at home and abroad.

Currently, AIM Vaccine has all five validated human vaccine platform technologies globally, including bacterial vaccine platform technologies, viral vaccine platform technologies, genetic engineering vaccine platform technologies, conjunctive vaccine platform technologies and mRNA vaccine platform technologies. In particular, AIM Vaccine has developed a strong advantage in next-generation vaccine technologies like mRNA technology platform. 

Recently, the company announced that two candidates of COVID-19 mRNA vaccine were approved for clinical trials in Pakistan. One targeting SARS-nCoV-2 mutant is approved for Phase I clinical trial, while the other targeting original COVID-19 virus is approved for Phase III clinical trial of sequential booster vaccination. 

It is reported that AIM Vaccine's bivalent mRNA vaccine against Omicron BA.5, first of its kind in China, has showed high rates of prevention, good results of safety and immunogenicity, and even broad spectrum of efficacy according to its experimental data.

Based on the same technology platform, AIM Vaccine may well possess great potential in a large number of unsatisfied clinical needs such as rabies vaccine renovation, HPV and tumor vaccines in the future.

With more clinical trial results to be released, R&D and commercial milestones of multiple potential blockbusters like PCV-13, quadrivalent meningococcal polysaccharide conjugate vaccine and bivalent EV71-CA HFMD vaccine, and investment of capitals, there are sufficient reasons to believe in AIM Vaccine to deliver innovative products with higher safety and better immunogenicity for humans. At the same time, AIM Vaccine is also expected to achieve rapid growth and realize its leadership.